Wolfson Institute of Preventive Medicine

Search - ZOO
Search - K2
Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks
Barts CTU Building

The Cancer Prevention Trials Unit (CPTU) opened in 2006 with core funding from Cancer Research UK.

In 2013 some new collaborations were established which lead to the unit broadening its remit which were reflected in a name change to the Barts CTU.

The Barts CTU is committed to supporting safe and appropriate sharing of data from its published trials.  To make a request, please contact Professor Peter Sasieni at This email address is being protected from spambots. You need JavaScript enabled to view it.

The new unit includes the following branches:

The Cancer Prevention Trials Unit (CPTU)

The CPTU specialises in prevention and screening by facilitating high quality clinical trial research and producing evidence based interventions to prevent a wide range of cancers.

The Centre for Experimental Cancer Medicine (CECM)

The Barts and Brighton ECMC facilitates the translation of basic scientific discovery into the delivery of novel treatments to patients with cancer.

The Experimental Medicine and Rheumatology clinical trial centre (EMR CTC)

The EMR CTC focuses on the research of cellular and molecular mechanisms of inflammation and autoimmunity in chronic arthritis with particular emphasis on translational research and biomarkers discovery. Studies being conducted at the EMR CTC focus on investigating whether synovial pathobiology can stratify biologic response in rheumatoid arthritis.

The Head and Neck surgical trials unit at the National Face, Oral and Oculoplastic Research Centre (NFORC)

The Royal College of Surgeons (RCS) has appointed NFORC as a Surgical Trials Unit specialising in head and neck surgery. The centre is working with Oral and MaxoFacial (OMF) and oculoplastic surgeons to develop research in their area.

Peter Sasieni
Clinical trials are essential for evaluating chemo-preventive strategies and screening technologies. We aim to enable more high quality trials to take place by providing innovative designs and taking care of the mechanics of clinical trials. I am fortunate to have a team with expertise in Good Clinical Practice, database design and quality assurance who are dedicated to uniting with leading scientists and the public to prevent cancer.
Prof. Peter Sasieni
Return to top